Targeted agents and immunotherapies: optimizing outcomes in melanoma

Key Points Clinical therapeutics for advanced-stage melanoma have improved dramatically with the development of BRAF and MEK inhibitors, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell-death protein 1 (PD-1) blocking antibodies, and a modified oncolytic herpes virus that is...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Clinical oncology Vol. 14; no. 8; pp. 463 - 482
Main Authors:	Luke, Jason J., Flaherty, Keith T., Ribas, Antoni, Long, Georgina V.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.08.2017 Nature Publishing Group
Subjects:	692/699/67/1059/2325 692/699/67/1059/602 692/699/67/1813/1634 692/700/565/1436/2185 692/700/565/251 Antigen presentation Antigens Biomarkers Blocking antibodies Care and treatment Cell death Clinical trials CTLA-4 protein Cytotoxicity Decision making Drug targeting FDA approval Humans Immune checkpoint Immunotherapy Lactose Lymphocytes T MAP kinase Medicine & Public Health MEK inhibitors Melanoma Melanoma - mortality Melanoma - secondary Melanoma - therapy Metastases Metastasis Molecular Targeted Therapy Neoplasm Metastasis Oncology Oncolysis Patient outcomes Patients PD-1 protein review-article Signal transduction Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Survival Analysis Treatment Outcome Tumors
ISSN:	1759-4774, 1759-4782, 1759-4782
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!